Relief Therapeutics - eine COVID-19 Hoffnung? (Seite 412)
eröffnet am 11.03.20 17:46:44 von
neuester Beitrag 05.04.24 14:53:43 von
neuester Beitrag 05.04.24 14:53:43 von
Beiträge: 14.078
ID: 1.321.697
ID: 1.321.697
Aufrufe heute: 0
Gesamt: 2.517.888
Gesamt: 2.517.888
Aktive User: 0
ISIN: CH1251125998 · WKN: A3EFB5 · Symbol: RLF
1,2600
CHF
+3,70 %
+0,0450 CHF
Letzter Kurs 18.04.24 SIX Swiss (CHF)
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 0,9300 | +54,46 | |
| 0,5055 | +41,91 | |
| 6,8200 | +36,95 | |
| 2,4700 | +33,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0550 | -22,71 | |
| 2,4400 | -22,78 | |
| 6,0500 | -22,93 | |
| 0,9000 | -23,08 | |
| 1,2250 | -38,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 69.239.901 von Alpsee1 am 04.09.21 20:31:41Quelle: https://www.nrxpharma.com
Sept 4, 2021
CEO Update: Ongoing Communications with the US Food and Drug Administration
NRx Pharmaceuticals continues to receive many requests for updates on the status of the US Food and Drug Administration’s (FDA) review of NRx’s application for Emergency Use Authorization (EUA) of ZYESAMI™ (aviptadil), to treat patients suffering from Critical COVID-19 with respiratory failure.
On September 3, 2021, NRx received a request for additional clinical information from the FDA, and plans to respond to this information request within a week. Ongoing conversations between the FDA and sponsor of any application to the FDA are normal, expected, and important to the FDA’s review process.
NRx has responded to three prior information requests since filing the EUA application on May 31, 2021. FDA’s review of NRx’s EUA application remains ongoing
CEO Update: Ongoing Communications with the US Food and Drug Administration
NRx Pharmaceuticals continues to receive many requests for updates on the status of the US Food and Drug Administration’s (FDA) review of NRx’s application for Emergency Use Authorization (EUA) of ZYESAMI™ (aviptadil), to treat patients suffering from Critical COVID-19 with respiratory failure.
On September 3, 2021, NRx received a request for additional clinical information from the FDA, and plans to respond to this information request within a week. Ongoing conversations between the FDA and sponsor of any application to the FDA are normal, expected, and important to the FDA’s review process.
NRx has responded to three prior information requests since filing the EUA application on May 31, 2021. FDA’s review of NRx’s EUA application remains ongoing
Wie lange will die FDA denn noch warten?
Oklahoma hospitals deluged by ivermectin overdoses, doctor says.
Jason McElyea says people overdosing on anti-parasitic drug that some people believe without evidence can cure or treat Covid.
https://www.theguardian.com/world/2021/sep/04/oklahoma-docto…
Oklahoma hospitals deluged by ivermectin overdoses, doctor says.
Jason McElyea says people overdosing on anti-parasitic drug that some people believe without evidence can cure or treat Covid.
https://www.theguardian.com/world/2021/sep/04/oklahoma-docto…
Aviptadil in der Liste der EMA aufgeführt
PunkassDerm28 minutes ago yahoo
Aviptadil
Relief Therapeutics Holding S.A
Other therapeutics
Clinical Phase
https://www.ema.europa.eu/en/human-regulatory/overview/publi…
Less
PunkassDerm28 minutes ago yahoo
Aviptadil
Relief Therapeutics Holding S.A
Other therapeutics
Clinical Phase
https://www.ema.europa.eu/en/human-regulatory/overview/publi…
Less
Also..
Nimmer schauen und hoffen in 5-10 Jahr sind wir Millionäre…😂😂 Trading Spotlight
D1 hour ago
https://twitter.com/realwillmeade/status/1433490064990949376
Reply

Jonathan Javitt2 hours ago
@icebear. As you know, our company has a very different focus than the company you compared us to. In addition to our work with aviptadil, we are focused on NRX-101 for suicidal depression and PTSD and on a promising new vaccine that targets COVID-19 and particularly the new variants that are threatening the effectiveness of first-generation vaccines. Our board, advisors, and management team include people who have unique expertise in areas of global security -- particularly biosecurity and health policy. In order to develop a vaccine that is rapidly tailored to new variants as they emerge, we must forge close alliances with organizations around the world whose job it is to detect and characterize those variants. In addition to the people you mentioned in your post, please also note that Dr. Dennis McBride, a former Professor at National Defense University and DARPA program officer serves as our Chief Strategy Officer and Dr. Stephen Cunnion, who led the US DOD response to the original SARS epidemic serves as a Global Medical Director. Both are highly decorated military officers. We face an unprecedented threat to the survival of many and we continue to build an enterprise that will hopefully play a meaningful role in countering that threat.
https://twitter.com/realwillmeade/status/1433490064990949376
Reply

Jonathan Javitt2 hours ago
@icebear. As you know, our company has a very different focus than the company you compared us to. In addition to our work with aviptadil, we are focused on NRX-101 for suicidal depression and PTSD and on a promising new vaccine that targets COVID-19 and particularly the new variants that are threatening the effectiveness of first-generation vaccines. Our board, advisors, and management team include people who have unique expertise in areas of global security -- particularly biosecurity and health policy. In order to develop a vaccine that is rapidly tailored to new variants as they emerge, we must forge close alliances with organizations around the world whose job it is to detect and characterize those variants. In addition to the people you mentioned in your post, please also note that Dr. Dennis McBride, a former Professor at National Defense University and DARPA program officer serves as our Chief Strategy Officer and Dr. Stephen Cunnion, who led the US DOD response to the original SARS epidemic serves as a Global Medical Director. Both are highly decorated military officers. We face an unprecedented threat to the survival of many and we continue to build an enterprise that will hopefully play a meaningful role in countering that threat.
YF NRXP
Andy10 minutes ago
Fintel finally updated. 100 shares available for shorting. Borrow interest fee is now 360%. Did shorties pay fintel to keep silence all day yesterday and today?
Andy10 minutes ago
Fintel finally updated. 100 shares available for shorting. Borrow interest fee is now 360%. Did shorties pay fintel to keep silence all day yesterday and today?
In D wurden gestern insgesamt 90000 Personen getestet, positiv ca. 9 %, in UK ca. 8000000 Tests und etwa 4,5% positiv, sogar in Israel viel mehr Tests als in D mit 130000. USA mit ca. 3 mal soviel Einwohnern 1,1 Mill. Tests und erstaunliche 14 % positiv, also sind US-Amerikaner offensichtlich am anfälligsten, was man auch an der riesigen Zahl der auf Intensivstation liegenden (25000) sehen kann. Die EUA für Zyesami wäre wohl ein Segen für das Land.
Kann jemand die geringe Testanzehl in D verstehen? Ist es immer noch ein heißer Kampf mit stundenlangen Anrufversuchen wie zu Anfang der Pandemie, bis man durchkommt? Ws eher nicht.Danke
Kann jemand die geringe Testanzehl in D verstehen? Ist es immer noch ein heißer Kampf mit stundenlangen Anrufversuchen wie zu Anfang der Pandemie, bis man durchkommt? Ws eher nicht.Danke
Antwort auf Beitrag Nr.: 69.221.382 von TomR7 am 02.09.21 16:02:28Sorry, das war wohl ein Missverständnis...
Dachte, die Phase 3 für den Inhaler sei abgeschlossen worden. Von Zulassung kann noch keine Rede sein. Muss mich wohl besser informieren
Dachte, die Phase 3 für den Inhaler sei abgeschlossen worden. Von Zulassung kann noch keine Rede sein. Muss mich wohl besser informieren
Vollzulassung Inhaler gestern ????
@alpsee1da liegst Du wahrscheinlich falsch.
Wenn Du die Zulassung in der Schweiz meinst, da hat gestern die Studie Phase 2 begonnen, siehe Beitrag von Dir selbst heute morgen
Oder hab ich da was falsch verstanden?
Durchsuchen
Relief Therapeutics - eine COVID-19 Hoffnung?
